Inhibrx, Inc. (NASDAQ:INBX - Get Free Report) was the recipient of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 1,220,000 shares, a decrease of 5.4% from the January 15th total of 1,290,000 shares. Approximately 12.3% of the company's stock are sold short. Based on an average trading volume of 86,400 shares, the days-to-cover ratio is currently 14.1 days.
Analyst Upgrades and Downgrades
Separately, JMP Securities reaffirmed a "market perform" rating on shares of Inhibrx in a research report on Wednesday, January 22nd.
View Our Latest Report on INBX
Inhibrx Trading Down 1.9 %
Shares of Inhibrx stock traded down $0.24 on Friday, reaching $12.56. 60,223 shares of the company were exchanged, compared to its average volume of 87,442. Inhibrx has a one year low of $10.80 and a one year high of $18.95. The company has a 50-day moving average of $13.86 and a 200 day moving average of $14.54.
Institutional Investors Weigh In On Inhibrx
A number of large investors have recently added to or reduced their stakes in the business. Sanofi bought a new position in shares of Inhibrx in the fourth quarter worth $17,832,000. HighTower Advisors LLC acquired a new position in shares of Inhibrx in the fourth quarter worth approximately $12,039,000. Walleye Capital LLC acquired a new position in shares of Inhibrx in the fourth quarter worth approximately $8,932,000. Slotnik Capital LLC acquired a new position in shares of Inhibrx in the fourth quarter worth approximately $5,975,000. Finally, Millennium Management LLC acquired a new position in Inhibrx in the fourth quarter valued at approximately $3,979,000. Institutional investors own 82.46% of the company's stock.
Inhibrx Company Profile
(
Get Free Report)
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Read More
Before you consider Inhibrx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx wasn't on the list.
While Inhibrx currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
